Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva: Product costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs: References

Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva
(2003; 199 pages)

Índice de contenido

	Summary: Observations and some ways forward
		A. Overall observations
		B. Experiences with fixed-dose combinations
		C. Public health priorities
		D. IP and legal options
		E. Pharmaceutical development, quality assurance, and regulatory requirements
	Welcome
		Objectives of the meeting
		Expected outcomes
		Presentations on TB FDC issues
		Presentations and discussions on malaria FDC issues
		Presentations and discussions concerning ARV FDCs
		Presentation and discussion of cross-cutting issues related to logistics, adherence and resistance with FDCs
		Procurement experiences
		Intellectual property and industry issues
		Regulatory issues
		Concluding session
	Fixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective
		Abstract
		Tuberculosis in the world of today
		Combination therapy and fixed-dose combination (FDC) formulations in the management of TB
		Registration requirements for rifampicin-containing FDC formulations
		Conclusions
		Acknowledgments
		Annex: Bioavailability of rifampicin, the Biopharmaceutic Classification System and the 4D approach to disease management
		Results/c results/comments
		References
	Product costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs
		Introduction
		Method
		Results
		Discussion
		References
	Fixed-dose combinations: artemisinin-based combination therapies for malaria treatment
		Introduction
		Background
		Implementation issues
		Process leading to the development of guidelines on the use of artemisinin-based combination therapies (ACTs)
		Support to countries in the implementation of ACTs
		Challenges/way forward
		Recommendations for further research
		Conclusion
		References
	Developing combinations of drugs for malaria examination of critical issues and lessons learnt
		Background
		Parasite resistance to antimalarial drugs: a major impediment to effective control
		Strategies to overcome resistance
		Evidence - the key to sensible recommendations
		Further work on the artemisinins
		Recommendations & outstanding challenges
		References
	Safety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India
		Abstract
		Introduction
		Methods
		Results
		Discussion
		Immunological improvement
		Viral load
		Clinical findings
		Conclusions
		References
	Effect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field
		Abstract
		Introduction
		Procurement
		Distribution
		Prescribing
		Dispensing to patients
		Cost to patient
		Patient use
		Consumption data
		Conclusion
		References
	Effect of fixed-dose combination (FDC) medications on adherence and treatment outcomes
		Introduction
		Evidence of effect of FDCs or unit-of-use packaging on adherence and treatment outcomes
		Research needs
		Conclusion
		Acknowledgements
		References
	Effect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper
		Executive summary
		Introduction
		Biological basis for drug resistance to anti-TB, HIV/AIDS and malaria drugs
		Combination drugs in the context of AMR
		Overcoming clinical resistance using combinations: what is the evidenceⁱ?
		Future research needs
		Conclusion
		Selected studies comparing combinations, FDCs, blister packs and monotherapy with regard to development of antimicrobial resistance
		References
	Fixed-dose combination (FDC) drugs availability and use as a global public health necessity: intellectual property and other legal issues
		Executive summary
		Introduction
		IPRs and Fixed-dose Combinations: Introduction to the “Anticommons Problem”
		IPRs and Fixed-dose Combinations: The “Anticommons Problem” (II)
		Overcoming IP/Legal barriers
		Back to the Future: TRIPS, Public Health, Access to Medicines
		Recommendations
		Conclusions
		References
	Pharmaceutical development and quality assurance of FDCs
		Abstract
		Introduction
		Preformulation studies
		Some examples of the relevance of the properties of the API to product formulation!
		Good Manufacturing Practice (GMP)
		Issues that may arise in the formulation of FDCs that do not arise for single entity products include:
		Changes to registered products (variations)
		Quality control of FDCs
		Recommendations
		References
	Annotated agenda
	List of participants

References

1. World Health Organization. Framework for effective tuberculosis control. WHO/TB/94.179. 1994.

2. Kamolratanakul P, Sawert H, Lertmaharit S et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999;93: 552-557.

3. Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-1184.

4. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Third edition WHO/CDS/TB/2003.313. 2003.

5. World Health Organization, International Union Against Tuberculosis and Lung Disease. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 1994;75:180-181.

6. World Health Organization, International Union Against Tuberculosis and Lung Disease. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization. Int J Tuberc Lung Dis 1999; 3:

7. World Health Organization. Essential Drugs. WHO Model List (revised December 1999). WHO Drug Information 1999;13:249-262.

8. Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999;3: S292-S300.

9. Laing RO, McGoldrick KM. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis 2000; 4: S194-S207.

10. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001;79: 61-68.

11. Management Sciences for Health. International Drug Price Indicator Guide. accessed on October 13, 2003 at http://erc.msh.org/dmpguide

12. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2003. Geneva, Switzerland, WHO/CDS/TB/2003.316.

13. Blomberg B, Evans P, Phanouvong S et al. Informal consultation on 4-drug fixed-dose combinations compliant with the WHO Model List of Essential Drugs, Geneva, Switzerland, 15-17 August 2001. Geneva: UNDP, World Bank, WHO Special Programme for Research & Training in Tropical Diseases (TDR); 2002. Report No.: TDR/TB/02.1, WHO/CDS/TB/2002.99.

14. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Resp Dis 1989; 140:1618-1622.

15. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-15.

16. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003; 63: 535-553.

17. Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954

18. Snider DE, Graczyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984;130: 1091-1094.

19. East African and British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils. Lancet 1978;2:8085 334-338.

20. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119: 579-585.

21. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association. Br J Dis Chest 1981;75:141-153.

22. Nunn P, Kibuga D, Gathua S et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;16: 627-30.

23. Pozniak AL, MacLeod GA et al. The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa. AIDS 1992;6:809-814.

24. Chintu C, Luo C, Bhat G et al. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch Dis Child 1993;68: 665-668.

25. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83: 183-186.